CSPIA
BIO icon

Cary Street Partners Investment Advisory’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16
Closed -$5.74K – 755
2023
Q3 		$5.74K Hold
16
– – ﹤0.01% 1437
2023
Q2 		$6.07K Buy
16
+3
+23% +$1.22K ﹤0.01% 1355
2023
Q1 		$6.23K Hold
13
– – ﹤0.01% 1271
2022
Q4 		$5.47K Buy
+13
New +$5.25K ﹤0.01% 1311

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Cary Street Partners Investment Advisory's BIO Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 16 shares — an estimated $5.74K sold.

Cary Street Partners Investment Advisory first reported a position in BIO in Q4 2022 and held it in 4 quarters. The position peaked at $6.23K in Q1 2023. 484 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 16 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $5.74K.
  • Cary Street Partners Investment Advisory first reported a position in Bio-Rad Laboratories Class A in Q4 2022 and held it in 4 quarters.
  • Cary Street Partners Investment Advisory's Bio-Rad Laboratories Class A position peaked at $6.23K in Q1 2023.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.